$QTRX

Quanterix Corp

Quanterix is a life sciences company that sells instruments and consumables for biomarker research and spatial biology, and provides contract research and clinical laboratory testing services. Its customers include research laboratories, contract research organizations, academic institutions, biopharmaceutical companies, and medical providers. Its Simoa technology measures low-concentration protein biomarkers in fluids, while its Spatial Biology platforms analyze proteins and cellular patterns in intact tissue. Products include the HD-X, SR-X and SP-X instruments, PhenoCycler and PhenoImager systems, assay kits, panels and reagents. Quanterix also operates the CLIA-certified Accelerator Laboratory in Bedford, Massachusetts, which offers research services and clinical tests through Lucent Diagnostics, including four laboratory-developed tests for neurological conditions. The company makes money from instrument and consumables sales, laboratory services, and extended-warranty and service contracts. It sells its instruments and related consumables worldwide. Quanterix is headquartered in Billerica, Massachusetts.

0
5
1

No SEC Form 4 filings for $QTRX in the last 30 days.

See all $QTRX insider activity →
Med

Quanterix Corp (QTRX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Quanterix Corp (QTRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Quanterix Announces Leadership Transition Plan Everett Cunningham Steps Down as President and CEO to Accept Another Opportunity Jim Gute, Quanterix’s Chief Commercial Officer, Appointed to the Additional Role of Interim President and CEO Board Has Initiated a Search

QTRX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 6 news stories mentioning QTRX (Quanterix Corp). Coverage has skewed bearish: 0 bullish, 5 neutral, and 1 bearish.

Recent QTRX coverage spans earnings, financial news and corporate actions.

What's driving QTRX

AlphAI scores every news story that mentions QTRX with an AI model for sentiment and relevance, and aggregates insider trades from Quanterix Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $QTRX

Score
$QTRXMedExec change· resigned

Quanterix Corp (QTRX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Quanterix Corp (QTRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Quanterix Announces Leadership Transition Plan Everett Cunningham Steps Down as President and CEO to Accept Another Opportunity Jim Gute, Quanterix’s Chief Commercial Officer, Appointed to the Additional Role of Interim President and CEO Board Has Initiated a Search

Quanterix Corporation Q3 2026 Earnings Call Summary

Quanterix reported Q3 2026 revenue growth of 6.3%, driven by commercial realignment and high utilization of spatial platforms. Management expects Q4 growth from Accelerator Lab conversions and 2027 diagnostics expansion. Florida Medicaid approved reimbursement for Alzheimer's biomarker testing at $484 per test. The company aims for cash flow breakeven in 2027 and regulatory milestones for the HD-X platform.

What Quanterix (QTRX) Said on Its Q3 Earnings Call

Quanterix (QTRX) reported a Q3 net loss of $21.6M, improved from last year. Adjusted EBITDA loss was $12.2M. Gross margin rose to 47.4%. LucentAD test volume doubled, but revenue from diagnostics fell to $1.2M. The company expects 2026 gross margin of 48-50% and $70M cash. Alzheimer's test discussions with FDA continue, with no clearance date given.

$QTRXMedEarnings

Quanterix Releases Financial Results for the Third Quarter of 2026

Quanterix Corp (QTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quanterix Releases Financial Results for the Third Quarter of 2026 Reports $35.0 million in revenue, up 6.3% sequentially, and $80.7 million of cash and marketable securities Initiatives to accelerate commercial effectiveness position the Company for growth in rest o

Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026

Quanterix (QTRX) announced global availability of its PhenoCode 2.0 Molecular Barcoding Kit and plans to ship TIME and high-plex ADC panels in Q4 2026. The company also launched Accelerator Laboratory Services for custom ADC panel development. Quanterix aims to advance spatial biology content, supported by its Content Innovation Engine and integration of Akoya Biosciences' platform.

Related tickers